Drug or intervention
Hydroxychloroquine Clinical Trials
Studies that test Hydroxychloroquine, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 92Genotype, Retinal Disease
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
Background: Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis.
- Trial name
- NCT01145196
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Eye Institute (NEI)
Sudden Hearing Loss
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours.
- Trial name
- NCT06467526
- Testing
- Hydroxychloroquine, Steroid
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Aging
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
This study tests whether certain medicines and a skin treatment can slow down or partly reverse the body's aging process. As people age, the activity of their genes changes in predictable ways.
- Trial name
- NCT07888595
- Testing
- Topical anti-aging peptide serum
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Frontiers in Bioscience Research Institute and Aging
IgA Nephropathy
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public…
- Trial name
- QUIgAN (NCT06350630)
- Testing
- Hydroxychloroquine Oral Tablet
- Where
- 8 sites in France
- Volunteers
- 334 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Rheumatic Fever, Rheumatic Heart Disease in Children
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis.
- Conditions
- Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease
- Trial name
- ACT4RHD (NCT07830108)
- Testing
- Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 600 people
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland
Primary Sjögren's Syndrome (pSS)
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab.
- Trial name
- NCT07852234
- Testing
- Blinatumomab, background treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tongren Hospital
Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy…
- Trial name
- QT-LIFE (NCT06652113)
- Testing
- hydroxychloroquine and levothyroxine, Levothyroxine
- Where
- 2 sites in China
- Volunteers
- 796 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sjögren's Disease, Interstitial Lung Disease
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
- Trial name
- NCT07843381
- Testing
- Telitacicept 160mg, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Interstitial Lung Disease
Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
- Trial name
- TIPS (NCT07443436)
- Testing
- Azithromycin 250 mg x3/week (3 tablets/week), Prednisone 10 mg/day, Hydroxychloroquine 400 mg/day
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
- Trial name
- AIMSS (NCT07825454)
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Completed, with results posted
All 66Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Chronic Kidney Disease, Cardiovascular Disease
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis
- Trial name
- MaCK (NCT03636152)
- Testing
- MRI carotid, APWV, Hydroxychloroquine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Pancreatic Cancer
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
A standard treatment for patients with pancreatic cancer is standard photon radiation in combination with the chemotherapy drug, capecitabine.
- Trial name
- NCT01494155
- Testing
- Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute